Convergent Therapeutics and NorthStar Medical Radioisotopes announce expanded partnership to support Convergent’s late-stage alpha-emitting radioantibody program

CAR-T Digest - August 2020

Weekly Digest - January 2026

6 January 2026: Convergent Therapeutics and NorthStar Medical Radioisotopes announce expanded partnership to support Convergent’s late-stage alpha-emitting radioantibody program

Convergent Therapeutics and NorthStar Medical Radioisotopes expanded their partnership to co-locate Convergent’s drug product manufacturing within NorthStar’s Beloit, Wisconsin campus
The expanded agreement secures large-scale, late-stage and commercial manufacturing capacity for Convergent’s lead alpha-emitting radioantibody program, CONV01-α, while establishing an integrated and reliable supply chain
Co-location is designed to drive efficiencies and economies of scale across both drug-product manufacturing and the production of high-purity Actinium-225 (Ac-225), addressing a key supply constraint for alpha-based radiotherapies
The partnership supports late-stage monotherapy studies of CONV01-α in metastatic castration-resistant prostate cancer (mCRPC), as well as future trials in earlier disease settings and combination regimens
Reliable access to Ac-225 and NorthStar’s state-of-the-art CDMO capabilities strengthens Convergent’s ability to advance CONV01-α toward pivotal studies and potential commercial launch, building on established clinical proof-of-concept and a differentiated safety profile ensure immediate supply upon approval